Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 1.91B | 1.92B | 1.73B | 1.11B | 699.54M |
Gross Profit | 527.62M | 618.96M | 365.34M | 309.44M | 163.65M |
EBITDA | 209.18M | 359.88M | 194.31M | 177.80M | 126.69M |
Net Income | -135.16M | 62.00M | -21.88M | 21.86M | -6.25M |
Balance Sheet | |||||
Total Assets | 2.72B | 2.75B | 2.90B | 1.96B | 1.63B |
Cash, Cash Equivalents and Short-Term Investments | 467.25M | 557.42M | 698.51M | 442.36M | 553.93M |
Total Debt | 437.79M | 362.99M | 452.49M | 471.69M | 244.97M |
Total Liabilities | 830.24M | 755.35M | 903.45M | 618.63M | 331.98M |
Stockholders Equity | 1.75B | 1.85B | 1.87B | 1.33B | 1.29B |
Cash Flow | |||||
Free Cash Flow | 123.58M | 245.30M | 100.63M | 19.18M | -233.39M |
Operating Cash Flow | 283.12M | 361.15M | 191.86M | 148.41M | 104.03M |
Investing Cash Flow | -174.72M | -245.37M | -210.65M | -392.72M | -157.94M |
Financing Cash Flow | -194.92M | -242.88M | 281.64M | 78.10M | 322.37M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
74 Outperform | HK$1.97B | 9.09 | 8.35% | 8.37% | 0.61% | -15.89% | |
61 Neutral | HK$895.36M | 11.23 | 7.39% | 4.99% | 0.20% | -36.95% | |
60 Neutral | HK$15.14B | 5.56 | -7.43% | 4.30% | 11.60% | -21.06% | |
54 Neutral | HK$2.27B | 33.92 | -7.51% | 1.10% | -0.56% | -323.09% |
C-MER Medical Holdings Limited has announced a new structure for its board of directors and committees, effective from June 1, 2025. This restructuring includes appointments of key individuals to various roles, which is expected to enhance the company’s governance and operational oversight, potentially impacting its strategic direction and stakeholder engagement positively.
C-MER Medical Holdings Limited announced significant changes in its leadership structure, with Dr. Lam Shun Chiu Dennis resigning as Chairman, Executive Director, and CEO to focus on clinical work and ophthalmic innovation. Despite his resignation, Dr. Lam will continue to contribute to the company as an ophthalmologist and senior advisor. The company also appointed Dr. Ko Wing Man as an independent non-executive director and vice chairman, and Mr. Li Ling Cheung Raymond as an independent non-executive director, enhancing its board with experienced professionals. These changes are expected to impact the company’s strategic direction and governance, potentially influencing its market positioning and stakeholder relations.
C-MER Eye Care Holdings Limited, a company incorporated in the Cayman Islands, announced the successful passing of all resolutions at its Annual General Meeting held on 19 May 2025. The resolutions included the approval of audited financial statements, declaration of a final dividend, re-election of executive directors, and granting of mandates for share repurchase and issuance. The results indicate strong shareholder support, with all resolutions receiving over 98% approval. This outcome reflects positively on the company’s governance and strategic direction, potentially reinforcing investor confidence.
C-MER Eye Care Holdings Limited has announced its upcoming Annual General Meeting scheduled for May 19, 2025, where key agenda items include the approval of financial statements, the declaration of a final dividend, and the re-election of executive directors. Additionally, the company seeks shareholder approval to repurchase up to 10% of its issued shares, a move that could enhance shareholder value and reflect confidence in the company’s financial health.